Skip to main content
Equibles

GLAND · Gland Pharma Limited

Use GLAND with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GLAND.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
3,308.70 INR +44.80 (+1.37%) At close · Nov 12
Rebalance outlook locked
Market Cap
545.97B INR
Shares
165.01M
Volume · Nov 12 223.91K Avg daily vol (3M) 499.88K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close3,308.70 INR Open3,268.50 INR Day3,268.50–3,347.00 INR 52W close1,596.80–3,308.70 INR Avg vol 30d458K Last earningsNov 6, 2026 DataNov 2020–Nov 2026

Latest documents

2026
Nov 6
Earnings call
Q2 FY27 revenue rises 23%, profit after tax rises 58%

Gland Pharma reported Q2 FY27 revenue of Rs. 18,336 million, up 23% year-on-year, and profit after tax of Rs 2,908 million, up 58% year-on-year.

3 source passages
For the second quarter of FI27, our consolidated revenues stood at Rs. 18,336 million, representing a growth of 23% year-on-year. Profit after tax for the quarters stood at Rs 2,908 million, representing growth of 58% year-on-year, despite the impact of significant higher R&D investment and temporary profitability pressure of Senexia rising from the annual shutdown period. On behalf of Gland Pharma, we conclude this conference. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▼10.4% 13.84B INR 2.05B INR '25 Q3 ▼7.3% 14.25B INR 1.87B INR '25 Q4 ▲7.4% 15.06B INR 2.15B INR '26 Q1 ▲5.8% 14.87B INR 1.84B INR '26 Q2 ▲22.5% 16.95B INR 2.61B INR '26 Q3 ▲22.3% 17.43B INR 3.67B INR '26 Q4 ▲19.6% 18.00B INR 3.17B INR '27 Q1 LATEST ▲23.3% 18.34B INR 2.91B INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 1,596.80 INR Now 3,308.70 INR · 100% Range high 3,308.70 INR
vs 200-day avg +41% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XNSE:GLAND +5.2% +8.4% +41.9% +6.9% +92.1%

Exchange listing

Market
XNSE
Ticker
GLAND
ISIN
INE068V01023
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.glandpharma.com/
Investor relations
https://glandpharma.com/investors/disclosures-under-regulation-46-lodr

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2026-08-11 20.00 INR
2025-08-14 18.00 INR
2024-08-16 20.00 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-06 Audio Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q4 2026 2026-05-15
    Earnings Call